GENE vs. IKT, APTO, COEP, ONVO, CHRO, CLDI, TCBP, FRTX, BCDA, and SRNE
Should you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include Inhibikase Therapeutics (IKT), Aptose Biosciences (APTO), Coeptis Therapeutics (COEP), Organovo (ONVO), Chromocell Therapeutics (CHRO), Calidi Biotherapeutics (CLDI), TC Biopharm (TCBP), Fresh Tracks Therapeutics (FRTX), BioCardia (BCDA), and Sorrento Therapeutics (SRNE). These companies are all part of the "biological products, except diagnostic" industry.
Inhibikase Therapeutics (NYSE:IKT) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Inhibikase Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Genetic Technologies received 155 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Inhibikase Therapeutics an outperform vote while only 55.33% of users gave Genetic Technologies an outperform vote.
Genetic Technologies has higher revenue and earnings than Inhibikase Therapeutics.
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 14.7% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 6.5% of Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Genetic Technologies had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Genetic Technologies and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.30 beat Genetic Technologies' score of 0.00 indicating that Genetic Technologies is being referred to more favorably in the news media.
Inhibikase Therapeutics' return on equity of 0.00% beat Genetic Technologies' return on equity.
Inhibikase Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 1,342.01%. Given Genetic Technologies' higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Genetic Technologies.
Summary
Inhibikase Therapeutics and Genetic Technologies tied by winning 7 of the 14 factors compared between the two stocks.
Get Genetic Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetic Technologies Competitors List
Related Companies and Tools
